GlassScriptPhysician profile
Robert W Schneider
NPI 1558643205
$748.42
in general payments reported to CMS, 2019-2025
16 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $92.06 · 2022: $134 · 2023: $73.91 · 2024: $80.29 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $125.00 | 2025 | Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $122.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.97 | 2021-2022 | |
| Pfizer INC. | $91.68 | 2021-2024 | |
| Glaxosmithkline, LLC. | $58.57 | 2022-2024 | Arexvy, Shingrix |
| Eisai INC. | $42.40 | 2025 | |
| Novo Nordisk INC | $31.82 | 2023 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $26.68 | 2024 | Watchman Flx |
| Horizon Therapeutics Plc | $26.28 | 2022 | |
| Sumitomo Pharma America, INC. | $22.22 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $21.68 | 2022 | |
| Shield Therapeutics INC | $21.21 | 2025 | |
| Alnylam Pharmaceuticals INC. | $20.38 | 2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $19.24 | 2022 | |
| Tolmar, INC. | $13.97 | 2025 | Jatenzo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reprise Biomedical, INC. | $12.72 | 2024 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.